Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of TNBC and OVCA cell lines in response to Azacitidine and Talazoparib

ABSTRACT: Gene expression profiling of TNBC and OVCA cell lines in response to Azacitidine and Talazoparib

PROVIDER: PRJNA631733 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling of TNBC and OVCA cell lines in response to Azacitidine and Talazoparib

Project description:Triple negative breast cancer and ovarian cancer cell lines were treated with Azacitidine, Talazoparib, or combination for a period of 10 days to assess global transcriptional response. The focus of these transcriptional studies were on the assessment of DNA repair and immune pathway alteration by the therapeutics under study with the aim of defining novel inducers of BRCAness.

2020-05-20 | GSE150298 | GEO

Gene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)

Project description:Triple negative breast cancer and ovarian cancer cells were treated with Azacitidine, Talazoparib, or combination for a period of 10 days to assess global transcriptional response. The focus of these transcriptional studies were on the assessment of DNA repair and immune pathway alteration.

2020-05-28 | GSE151317 | GEO

Gene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)

Project description:Gene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)

| PRJNA635430 | ENA

RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib

Project description:We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib

2020-04-10 | GSE125206 | GEO

microRNA profiling of luminal and TNBC breast cancer cell lines

Project description:two luminal cell lines were added, MCF7 and BT-474 two TNBC cell line were added, MB231 and BT-549 microRNA expression profiles were conpared between the luminal group and the TNBC group

2014-10-03 | E-GEOD-62022 | biostudies-arrayexpress

Quantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line

Project description:To explore the molecular mechanisms by which romidepsin potentiates the effect of talazoparib, RNA sequencing analysis of MBL2 cell lines treated with talazoparib, romidepsin, or talazoparib plus romidepsin was performed. 40% of the 2023 genes in combination were from talazoparib, whereas only 5.9% of the genes deregulated during the treatment with the combination of talazoparib plus romidepsin were from the effect of romidepsin. 94 genes were presented in all three treatment groups and included upregulation of Prdm1, Dusp5, and CD74, among others. Analysis of genes responsible for DNA repair, cell cycle arrest and apoptosis demonstrated the contribution of romidepsin to downregulation of DNA repair, the synergistic effect of romidepsin and talazoparib on downregulation of genes of cell cycle leading to cell cycle arrest, and activation of apoptosis by talazoparib predominantly.

2020-09-04 | GSE157434 | GEO

microRNA profiling of luminal and TNBC breast cancer cell lines

Project description:two luminal cell lines were added, MCF7 and BT-474 two TNBC cell line were added, MB231 and BT-549

2014-10-03 | GSE62022 | GEO

Gene expression profiling of colorectal cancer cell lines after treatment with talazoparib

Project description:Gene expression profiling of colorectal cancer cell lines after treatment with talazoparib

| PRJNA589059 | ENA

RNA-seq profiling of NSCLC cell lines exposed to the PARP inhibitor talazoparib.

Project description:RNA-seq profiling of NSCLC cell lines exposed to the PARP inhibitor talazoparib.

| PRJEB30090 | ENA

Gene expression profile of azacitidine- and decitabine- resistant HTLV-1-infected cell lines

Project description:We generated azacitidine (AZA)- and decitabine (DAC)-resistant (AZA-R and DAC-R, respectively) cells from drug-sensitive ATL cell lines TL-Om1 and MT-2 via long-term drug exposure. To identify molecular mechanisms responsible for acquired resistance, we performed transcriptome analysis using Clariom S microarray.

2021-11-30 | GSE166980 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data